PMC:7441777 / 3568-5249 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid-PD-FMA-UBERON

    {"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T14","span":{"begin":48,"end":51},"obj":"Body_part"},{"id":"T15","span":{"begin":62,"end":65},"obj":"Body_part"},{"id":"T16","span":{"begin":194,"end":197},"obj":"Body_part"},{"id":"T17","span":{"begin":198,"end":204},"obj":"Body_part"},{"id":"T18","span":{"begin":864,"end":867},"obj":"Body_part"},{"id":"T19","span":{"begin":1156,"end":1159},"obj":"Body_part"},{"id":"T20","span":{"begin":1619,"end":1629},"obj":"Body_part"}],"attributes":[{"id":"A14","pred":"fma_id","subj":"T14","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A15","pred":"fma_id","subj":"T15","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A16","pred":"fma_id","subj":"T16","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A17","pred":"fma_id","subj":"T17","obj":"http://purl.org/sig/ont/fma/fma84116"},{"id":"A18","pred":"fma_id","subj":"T18","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A19","pred":"fma_id","subj":"T19","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A20","pred":"fma_id","subj":"T20","obj":"http://purl.org/sig/ont/fma/fma82740"}],"text":"Another potential drug target for SARS-CoV-2 is RNA‐dependent RNA polymerase (RdRp) (Figure 1), which is a key component of the replication machinery of the virus to make multiple copies of the RNA genome (Elfiky 2020c). RdRp in various coronaviruses are remarkably similar. For example, the RdRp of SARS-CoV exhibits ∼97% sequence similarity with that of SARS-CoV-2. More importantly, there is no human polymerase counterpart that resembles the sequence/structural homology with RdRp from coronaviruses, and hence, the development of RdRp inhibitors could be a potential therapeutic strategy without risk of crosstalk with human polymerases (Borgio et al., 2020; Subissi et al., 2014; Zhai et al., 2005). Very recently, Yin et al. reported the crystal structure RdRp of SARS-CoV-2 complexed with an antiviral drug, Remdesivir highlighting how the template-primer RNA is recognized by the polymerase enzyme and the chain elongation is inhibited by Remdesivir providing a basis for developing a wide range of effective inhibitors to overcome from SARS-CoV-2 infection (Yin et al., 2020). RdRp has been found to be an effective drug target for several other RNA viruses, spanning from the hepatitis C virus, zika virus to coronaviruses (Elfiky, 2017, 2019; Ganesan \u0026 Barakat, 2017). The active site of RdRp is highly conserved, and the catalytic domains contain two consecutive aspartate residues in a beta-turn joining β15 and β16 (Elfiky 2020c). The general structure of RdRp consists of 7 motifs (A to G) among them inner channel of catalytic sites represented by motif A to C, and they play a crucial role during the nucleotide addition cycle (Jia \u0026 Gong, 2019; Wu \u0026 Gong, 2018)."}

    LitCovid-PD-MONDO

    {"project":"LitCovid-PD-MONDO","denotations":[{"id":"T24","span":{"begin":34,"end":42},"obj":"Disease"},{"id":"T25","span":{"begin":300,"end":308},"obj":"Disease"},{"id":"T26","span":{"begin":356,"end":364},"obj":"Disease"},{"id":"T27","span":{"begin":771,"end":779},"obj":"Disease"},{"id":"T28","span":{"begin":1046,"end":1054},"obj":"Disease"},{"id":"T29","span":{"begin":1057,"end":1066},"obj":"Disease"},{"id":"T30","span":{"begin":1187,"end":1198},"obj":"Disease"},{"id":"T31","span":{"begin":1187,"end":1196},"obj":"Disease"}],"attributes":[{"id":"A24","pred":"mondo_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A25","pred":"mondo_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A26","pred":"mondo_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A27","pred":"mondo_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A28","pred":"mondo_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A29","pred":"mondo_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A30","pred":"mondo_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/MONDO_0005231"},{"id":"A31","pred":"mondo_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/MONDO_0002251"}],"text":"Another potential drug target for SARS-CoV-2 is RNA‐dependent RNA polymerase (RdRp) (Figure 1), which is a key component of the replication machinery of the virus to make multiple copies of the RNA genome (Elfiky 2020c). RdRp in various coronaviruses are remarkably similar. For example, the RdRp of SARS-CoV exhibits ∼97% sequence similarity with that of SARS-CoV-2. More importantly, there is no human polymerase counterpart that resembles the sequence/structural homology with RdRp from coronaviruses, and hence, the development of RdRp inhibitors could be a potential therapeutic strategy without risk of crosstalk with human polymerases (Borgio et al., 2020; Subissi et al., 2014; Zhai et al., 2005). Very recently, Yin et al. reported the crystal structure RdRp of SARS-CoV-2 complexed with an antiviral drug, Remdesivir highlighting how the template-primer RNA is recognized by the polymerase enzyme and the chain elongation is inhibited by Remdesivir providing a basis for developing a wide range of effective inhibitors to overcome from SARS-CoV-2 infection (Yin et al., 2020). RdRp has been found to be an effective drug target for several other RNA viruses, spanning from the hepatitis C virus, zika virus to coronaviruses (Elfiky, 2017, 2019; Ganesan \u0026 Barakat, 2017). The active site of RdRp is highly conserved, and the catalytic domains contain two consecutive aspartate residues in a beta-turn joining β15 and β16 (Elfiky 2020c). The general structure of RdRp consists of 7 motifs (A to G) among them inner channel of catalytic sites represented by motif A to C, and they play a crucial role during the nucleotide addition cycle (Jia \u0026 Gong, 2019; Wu \u0026 Gong, 2018)."}

    LitCovid-PD-CLO

    {"project":"LitCovid-PD-CLO","denotations":[{"id":"T21","span":{"begin":105,"end":106},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T22","span":{"begin":157,"end":162},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T23","span":{"begin":398,"end":403},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T24","span":{"begin":560,"end":561},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T25","span":{"begin":624,"end":629},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T26","span":{"begin":969,"end":970},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T27","span":{"begin":992,"end":993},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T28","span":{"begin":1092,"end":1095},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T29","span":{"begin":1160,"end":1167},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T30","span":{"begin":1199,"end":1204},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T31","span":{"begin":1211,"end":1216},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T32","span":{"begin":1285,"end":1291},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T33","span":{"begin":1398,"end":1399},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T34","span":{"begin":1498,"end":1499},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T35","span":{"begin":1571,"end":1572},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T36","span":{"begin":1593,"end":1594},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T37","span":{"begin":1675,"end":1679},"obj":"http://purl.obolibrary.org/obo/CLO_0001185"}],"text":"Another potential drug target for SARS-CoV-2 is RNA‐dependent RNA polymerase (RdRp) (Figure 1), which is a key component of the replication machinery of the virus to make multiple copies of the RNA genome (Elfiky 2020c). RdRp in various coronaviruses are remarkably similar. For example, the RdRp of SARS-CoV exhibits ∼97% sequence similarity with that of SARS-CoV-2. More importantly, there is no human polymerase counterpart that resembles the sequence/structural homology with RdRp from coronaviruses, and hence, the development of RdRp inhibitors could be a potential therapeutic strategy without risk of crosstalk with human polymerases (Borgio et al., 2020; Subissi et al., 2014; Zhai et al., 2005). Very recently, Yin et al. reported the crystal structure RdRp of SARS-CoV-2 complexed with an antiviral drug, Remdesivir highlighting how the template-primer RNA is recognized by the polymerase enzyme and the chain elongation is inhibited by Remdesivir providing a basis for developing a wide range of effective inhibitors to overcome from SARS-CoV-2 infection (Yin et al., 2020). RdRp has been found to be an effective drug target for several other RNA viruses, spanning from the hepatitis C virus, zika virus to coronaviruses (Elfiky, 2017, 2019; Ganesan \u0026 Barakat, 2017). The active site of RdRp is highly conserved, and the catalytic domains contain two consecutive aspartate residues in a beta-turn joining β15 and β16 (Elfiky 2020c). The general structure of RdRp consists of 7 motifs (A to G) among them inner channel of catalytic sites represented by motif A to C, and they play a crucial role during the nucleotide addition cycle (Jia \u0026 Gong, 2019; Wu \u0026 Gong, 2018)."}

    LitCovid-PD-CHEBI

    {"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T40","span":{"begin":18,"end":22},"obj":"Chemical"},{"id":"T41","span":{"begin":540,"end":550},"obj":"Chemical"},{"id":"T42","span":{"begin":800,"end":814},"obj":"Chemical"},{"id":"T43","span":{"begin":800,"end":809},"obj":"Chemical"},{"id":"T44","span":{"begin":810,"end":814},"obj":"Chemical"},{"id":"T45","span":{"begin":1018,"end":1028},"obj":"Chemical"},{"id":"T46","span":{"begin":1126,"end":1130},"obj":"Chemical"},{"id":"T47","span":{"begin":1376,"end":1385},"obj":"Chemical"},{"id":"T50","span":{"begin":1400,"end":1404},"obj":"Chemical"},{"id":"T51","span":{"begin":1619,"end":1629},"obj":"Chemical"}],"attributes":[{"id":"A40","pred":"chebi_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A41","pred":"chebi_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A42","pred":"chebi_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/CHEBI_36044"},{"id":"A43","pred":"chebi_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A44","pred":"chebi_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A45","pred":"chebi_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A46","pred":"chebi_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A47","pred":"chebi_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/CHEBI_132943"},{"id":"A48","pred":"chebi_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/CHEBI_29995"},{"id":"A49","pred":"chebi_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/CHEBI_72314"},{"id":"A50","pred":"chebi_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/CHEBI_10545"},{"id":"A51","pred":"chebi_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/CHEBI_36976"}],"text":"Another potential drug target for SARS-CoV-2 is RNA‐dependent RNA polymerase (RdRp) (Figure 1), which is a key component of the replication machinery of the virus to make multiple copies of the RNA genome (Elfiky 2020c). RdRp in various coronaviruses are remarkably similar. For example, the RdRp of SARS-CoV exhibits ∼97% sequence similarity with that of SARS-CoV-2. More importantly, there is no human polymerase counterpart that resembles the sequence/structural homology with RdRp from coronaviruses, and hence, the development of RdRp inhibitors could be a potential therapeutic strategy without risk of crosstalk with human polymerases (Borgio et al., 2020; Subissi et al., 2014; Zhai et al., 2005). Very recently, Yin et al. reported the crystal structure RdRp of SARS-CoV-2 complexed with an antiviral drug, Remdesivir highlighting how the template-primer RNA is recognized by the polymerase enzyme and the chain elongation is inhibited by Remdesivir providing a basis for developing a wide range of effective inhibitors to overcome from SARS-CoV-2 infection (Yin et al., 2020). RdRp has been found to be an effective drug target for several other RNA viruses, spanning from the hepatitis C virus, zika virus to coronaviruses (Elfiky, 2017, 2019; Ganesan \u0026 Barakat, 2017). The active site of RdRp is highly conserved, and the catalytic domains contain two consecutive aspartate residues in a beta-turn joining β15 and β16 (Elfiky 2020c). The general structure of RdRp consists of 7 motifs (A to G) among them inner channel of catalytic sites represented by motif A to C, and they play a crucial role during the nucleotide addition cycle (Jia \u0026 Gong, 2019; Wu \u0026 Gong, 2018)."}

    LitCovid-PubTator

    {"project":"LitCovid-PubTator","denotations":[{"id":"162","span":{"begin":78,"end":82},"obj":"Gene"},{"id":"163","span":{"begin":221,"end":225},"obj":"Gene"},{"id":"164","span":{"begin":480,"end":484},"obj":"Gene"},{"id":"165","span":{"begin":535,"end":539},"obj":"Gene"},{"id":"166","span":{"begin":1087,"end":1091},"obj":"Gene"},{"id":"167","span":{"begin":1300,"end":1304},"obj":"Gene"},{"id":"168","span":{"begin":1426,"end":1429},"obj":"Gene"},{"id":"169","span":{"begin":1471,"end":1475},"obj":"Gene"},{"id":"170","span":{"begin":1418,"end":1421},"obj":"Gene"},{"id":"171","span":{"begin":763,"end":767},"obj":"Gene"},{"id":"172","span":{"begin":292,"end":296},"obj":"Gene"},{"id":"173","span":{"begin":34,"end":44},"obj":"Species"},{"id":"174","span":{"begin":237,"end":250},"obj":"Species"},{"id":"175","span":{"begin":300,"end":308},"obj":"Species"},{"id":"176","span":{"begin":356,"end":366},"obj":"Species"},{"id":"177","span":{"begin":398,"end":403},"obj":"Species"},{"id":"178","span":{"begin":490,"end":503},"obj":"Species"},{"id":"179","span":{"begin":624,"end":629},"obj":"Species"},{"id":"180","span":{"begin":771,"end":781},"obj":"Species"},{"id":"181","span":{"begin":1187,"end":1204},"obj":"Species"},{"id":"182","span":{"begin":1206,"end":1216},"obj":"Species"},{"id":"183","span":{"begin":1220,"end":1233},"obj":"Species"},{"id":"184","span":{"begin":816,"end":826},"obj":"Chemical"},{"id":"185","span":{"begin":948,"end":958},"obj":"Chemical"},{"id":"186","span":{"begin":1376,"end":1385},"obj":"Chemical"},{"id":"187","span":{"begin":1046,"end":1066},"obj":"Disease"}],"attributes":[{"id":"A162","pred":"tao:has_database_id","subj":"162","obj":"Gene:43740578"},{"id":"A163","pred":"tao:has_database_id","subj":"163","obj":"Gene:43740578"},{"id":"A164","pred":"tao:has_database_id","subj":"164","obj":"Gene:43740578"},{"id":"A165","pred":"tao:has_database_id","subj":"165","obj":"Gene:43740578"},{"id":"A166","pred":"tao:has_database_id","subj":"166","obj":"Gene:43740578"},{"id":"A167","pred":"tao:has_database_id","subj":"167","obj":"Gene:43740578"},{"id":"A168","pred":"tao:has_database_id","subj":"168","obj":"Gene:28910"},{"id":"A169","pred":"tao:has_database_id","subj":"169","obj":"Gene:43740578"},{"id":"A170","pred":"tao:has_database_id","subj":"170","obj":"Gene:28934"},{"id":"A171","pred":"tao:has_database_id","subj":"171","obj":"Gene:43740578"},{"id":"A172","pred":"tao:has_database_id","subj":"172","obj":"Gene:43740578"},{"id":"A173","pred":"tao:has_database_id","subj":"173","obj":"Tax:2697049"},{"id":"A174","pred":"tao:has_database_id","subj":"174","obj":"Tax:11118"},{"id":"A175","pred":"tao:has_database_id","subj":"175","obj":"Tax:694009"},{"id":"A176","pred":"tao:has_database_id","subj":"176","obj":"Tax:2697049"},{"id":"A177","pred":"tao:has_database_id","subj":"177","obj":"Tax:9606"},{"id":"A178","pred":"tao:has_database_id","subj":"178","obj":"Tax:11118"},{"id":"A179","pred":"tao:has_database_id","subj":"179","obj":"Tax:9606"},{"id":"A180","pred":"tao:has_database_id","subj":"180","obj":"Tax:2697049"},{"id":"A181","pred":"tao:has_database_id","subj":"181","obj":"Tax:11103"},{"id":"A182","pred":"tao:has_database_id","subj":"182","obj":"Tax:64320"},{"id":"A183","pred":"tao:has_database_id","subj":"183","obj":"Tax:11118"},{"id":"A184","pred":"tao:has_database_id","subj":"184","obj":"MESH:C000606551"},{"id":"A185","pred":"tao:has_database_id","subj":"185","obj":"MESH:C000606551"},{"id":"A186","pred":"tao:has_database_id","subj":"186","obj":"MESH:D001224"},{"id":"A187","pred":"tao:has_database_id","subj":"187","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Another potential drug target for SARS-CoV-2 is RNA‐dependent RNA polymerase (RdRp) (Figure 1), which is a key component of the replication machinery of the virus to make multiple copies of the RNA genome (Elfiky 2020c). RdRp in various coronaviruses are remarkably similar. For example, the RdRp of SARS-CoV exhibits ∼97% sequence similarity with that of SARS-CoV-2. More importantly, there is no human polymerase counterpart that resembles the sequence/structural homology with RdRp from coronaviruses, and hence, the development of RdRp inhibitors could be a potential therapeutic strategy without risk of crosstalk with human polymerases (Borgio et al., 2020; Subissi et al., 2014; Zhai et al., 2005). Very recently, Yin et al. reported the crystal structure RdRp of SARS-CoV-2 complexed with an antiviral drug, Remdesivir highlighting how the template-primer RNA is recognized by the polymerase enzyme and the chain elongation is inhibited by Remdesivir providing a basis for developing a wide range of effective inhibitors to overcome from SARS-CoV-2 infection (Yin et al., 2020). RdRp has been found to be an effective drug target for several other RNA viruses, spanning from the hepatitis C virus, zika virus to coronaviruses (Elfiky, 2017, 2019; Ganesan \u0026 Barakat, 2017). The active site of RdRp is highly conserved, and the catalytic domains contain two consecutive aspartate residues in a beta-turn joining β15 and β16 (Elfiky 2020c). The general structure of RdRp consists of 7 motifs (A to G) among them inner channel of catalytic sites represented by motif A to C, and they play a crucial role during the nucleotide addition cycle (Jia \u0026 Gong, 2019; Wu \u0026 Gong, 2018)."}

    LitCovid-sentences

    {"project":"LitCovid-sentences","denotations":[{"id":"T33","span":{"begin":0,"end":220},"obj":"Sentence"},{"id":"T34","span":{"begin":221,"end":274},"obj":"Sentence"},{"id":"T35","span":{"begin":275,"end":367},"obj":"Sentence"},{"id":"T36","span":{"begin":368,"end":705},"obj":"Sentence"},{"id":"T37","span":{"begin":706,"end":1086},"obj":"Sentence"},{"id":"T38","span":{"begin":1087,"end":1280},"obj":"Sentence"},{"id":"T39","span":{"begin":1281,"end":1445},"obj":"Sentence"},{"id":"T40","span":{"begin":1446,"end":1681},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Another potential drug target for SARS-CoV-2 is RNA‐dependent RNA polymerase (RdRp) (Figure 1), which is a key component of the replication machinery of the virus to make multiple copies of the RNA genome (Elfiky 2020c). RdRp in various coronaviruses are remarkably similar. For example, the RdRp of SARS-CoV exhibits ∼97% sequence similarity with that of SARS-CoV-2. More importantly, there is no human polymerase counterpart that resembles the sequence/structural homology with RdRp from coronaviruses, and hence, the development of RdRp inhibitors could be a potential therapeutic strategy without risk of crosstalk with human polymerases (Borgio et al., 2020; Subissi et al., 2014; Zhai et al., 2005). Very recently, Yin et al. reported the crystal structure RdRp of SARS-CoV-2 complexed with an antiviral drug, Remdesivir highlighting how the template-primer RNA is recognized by the polymerase enzyme and the chain elongation is inhibited by Remdesivir providing a basis for developing a wide range of effective inhibitors to overcome from SARS-CoV-2 infection (Yin et al., 2020). RdRp has been found to be an effective drug target for several other RNA viruses, spanning from the hepatitis C virus, zika virus to coronaviruses (Elfiky, 2017, 2019; Ganesan \u0026 Barakat, 2017). The active site of RdRp is highly conserved, and the catalytic domains contain two consecutive aspartate residues in a beta-turn joining β15 and β16 (Elfiky 2020c). The general structure of RdRp consists of 7 motifs (A to G) among them inner channel of catalytic sites represented by motif A to C, and they play a crucial role during the nucleotide addition cycle (Jia \u0026 Gong, 2019; Wu \u0026 Gong, 2018)."}

    LitCovid-PD-HP

    {"project":"LitCovid-PD-HP","denotations":[{"id":"T6","span":{"begin":1187,"end":1196},"obj":"Phenotype"}],"attributes":[{"id":"A6","pred":"hp_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/HP_0012115"}],"text":"Another potential drug target for SARS-CoV-2 is RNA‐dependent RNA polymerase (RdRp) (Figure 1), which is a key component of the replication machinery of the virus to make multiple copies of the RNA genome (Elfiky 2020c). RdRp in various coronaviruses are remarkably similar. For example, the RdRp of SARS-CoV exhibits ∼97% sequence similarity with that of SARS-CoV-2. More importantly, there is no human polymerase counterpart that resembles the sequence/structural homology with RdRp from coronaviruses, and hence, the development of RdRp inhibitors could be a potential therapeutic strategy without risk of crosstalk with human polymerases (Borgio et al., 2020; Subissi et al., 2014; Zhai et al., 2005). Very recently, Yin et al. reported the crystal structure RdRp of SARS-CoV-2 complexed with an antiviral drug, Remdesivir highlighting how the template-primer RNA is recognized by the polymerase enzyme and the chain elongation is inhibited by Remdesivir providing a basis for developing a wide range of effective inhibitors to overcome from SARS-CoV-2 infection (Yin et al., 2020). RdRp has been found to be an effective drug target for several other RNA viruses, spanning from the hepatitis C virus, zika virus to coronaviruses (Elfiky, 2017, 2019; Ganesan \u0026 Barakat, 2017). The active site of RdRp is highly conserved, and the catalytic domains contain two consecutive aspartate residues in a beta-turn joining β15 and β16 (Elfiky 2020c). The general structure of RdRp consists of 7 motifs (A to G) among them inner channel of catalytic sites represented by motif A to C, and they play a crucial role during the nucleotide addition cycle (Jia \u0026 Gong, 2019; Wu \u0026 Gong, 2018)."}

    2_test

    {"project":"2_test","denotations":[{"id":"32720577-32399096-56195091","span":{"begin":658,"end":662},"obj":"32399096"},{"id":"32720577-25197083-56195092","span":{"begin":680,"end":684},"obj":"25197083"},{"id":"32720577-30324891-56195093","span":{"begin":1249,"end":1253},"obj":"30324891"},{"id":"32720577-28164720-56195094","span":{"begin":1274,"end":1278},"obj":"28164720"},{"id":"32720577-31507560-56195095","span":{"begin":1658,"end":1662},"obj":"31507560"}],"text":"Another potential drug target for SARS-CoV-2 is RNA‐dependent RNA polymerase (RdRp) (Figure 1), which is a key component of the replication machinery of the virus to make multiple copies of the RNA genome (Elfiky 2020c). RdRp in various coronaviruses are remarkably similar. For example, the RdRp of SARS-CoV exhibits ∼97% sequence similarity with that of SARS-CoV-2. More importantly, there is no human polymerase counterpart that resembles the sequence/structural homology with RdRp from coronaviruses, and hence, the development of RdRp inhibitors could be a potential therapeutic strategy without risk of crosstalk with human polymerases (Borgio et al., 2020; Subissi et al., 2014; Zhai et al., 2005). Very recently, Yin et al. reported the crystal structure RdRp of SARS-CoV-2 complexed with an antiviral drug, Remdesivir highlighting how the template-primer RNA is recognized by the polymerase enzyme and the chain elongation is inhibited by Remdesivir providing a basis for developing a wide range of effective inhibitors to overcome from SARS-CoV-2 infection (Yin et al., 2020). RdRp has been found to be an effective drug target for several other RNA viruses, spanning from the hepatitis C virus, zika virus to coronaviruses (Elfiky, 2017, 2019; Ganesan \u0026 Barakat, 2017). The active site of RdRp is highly conserved, and the catalytic domains contain two consecutive aspartate residues in a beta-turn joining β15 and β16 (Elfiky 2020c). The general structure of RdRp consists of 7 motifs (A to G) among them inner channel of catalytic sites represented by motif A to C, and they play a crucial role during the nucleotide addition cycle (Jia \u0026 Gong, 2019; Wu \u0026 Gong, 2018)."}